Vicapsys Life Sciences IncOTC Pink - Limited Information:VICP
- LAST PRICE0.9899
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.9899
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | VICP |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vicapsys Life Sciences Inc | 31.7M | -30.2x | --- |
Surrozen Inc | 31.6M | -0.5x | --- |
Sensei Biotherapeutics Inc | 31.6M | -1.4x | --- |
Viracta Therapeutics Inc | 32.2M | -0.6x | --- |
Achilles Therapeutics PLC | 31.2M | -0.4x | --- |
NKGen Biotech Inc | 32.8M | -0.3x | --- |
Company Information
Vicapsys Life Sciences, Inc. develops and commercializes, on a worldwide basis, various intellectual property rights relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. It also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
Contact Information
- Headquarters
- 1735 Buford Highway, Ste. 215-113CUMMING, GA, United States 30041
- Phone
- 470-514-4013
- Fax
- ---
Executives
- Chief Executive Officer, Executive Chairman of the Board
- Federico Pier
- Chief Financial Officer
- Jeffery Wright
- Director
- Dorothy Jordan
- Independent Director
- Colleen Delaney
- Independent Director
- Charles Farrahar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.03 |
Book Value | $-0.03 |
P/E Ratio | -30.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
